Brought to you by 
Light Sciences raises $40.1mm via Series C
16 Jul 2008
Executive Summary
Light Sciences Oncology (light-activated cancer drug therapy) raised $40.1mm through a Series C private placement to undisclosed investors. The company is planning to use the proceeds to continue development of its Litx (Light Infusion Therapy) candidate, which is in Phase III for hepatocellular carcinoma and metastatic colorectal cancer. Other Phase III trials are also set for brain cancer, as well as Phase I/II studies for benign prostatic hyperplasia.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Light Sciences raises $40.1mm via Series C
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice